Biopharmaceutics is a pivotal field within the Food and Drug Administration's (FDA) purview, where the intersection of biology and pharmaceuticals takes center stage. This discipline focuses on the study of how drugs are absorbed, distributed, metabolized, and excreted by the body, with a keen eye on the biological factors influencing drug performance.
The FDA plays a crucial role in evaluating the safety and efficacy of biopharmaceuticals, ensuring that these innovative drugs meet rigorous standards before reaching the market. This involves a comprehensive assessment of the biological and chemical properties of these compounds, understanding their behavior in the human body, and predicting their therapeutic impact.
The dynamic landscape of biopharmaceutics aligns with the FDA's commitment to advancing public health by fostering the development of cutting-edge therapies. By staying at the forefront of scientific advancements, the FDA continues to navigate the evolving terrain of biopharmaceutics, contributing to the approval of novel, life-changing treatments that meet the highest standards of quality and effectiveness.
Title : Hepatotoxic botanicals-shadows of pearls
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Development of novel drug delivery pathways enabled by perillyl alcohol (NEO100), A monoterpene with multifaceted biomedical applications
Axel H Schonthal, University of Southern California, United States
Title : From marker to mechanism: Ligand discovery enables functional analysis of OR51E1, an ectopic olfactory receptor, in prostate cancer
Vladlen Slepak, University of Miami, United States
Title : The impact of metal-decorated polymeric nanodots on proton relaxivity
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Principles and standards for managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model based on design-inspired biotech- & biopharma-driven applications to secure the human healthcare and biosafety
Sergey Suchkov, N D Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : R&D consultancy at the medicines discovery catapult: De-risking drug discovery for innovators
Adriana Gambardella, Medicine Discovery Catapult, United Kingdom
Title : Biocompatible synthesis of non crystalline iron oxide nanoparticles with stable colloidal properties
Lan Wang, Paretor LLC, United States
Title : Hydrogen sulfide in sepsis: From bench to bedside
Madhav Bhatia, University of Otago, New Zealand
Title : Biocompatibility and subcutaneous host response to silk fibroin–chitosan composite plugs: Progress toward biodegradable implant materials
Luis Jesus Villarreal Gomez, Universidad Autónoma de Baja California, Mexico